Synomics, BioScience Labs Partner for Phase I Services

Synomics Pharma and BioScience Laboratories have partnered to provide integrated topical Phase I study services for trials in healthy human subjects. The partnership combines Synomics Pharma’s preclinical and clinical bioanalysis and analytical chemistry services with BioScience’s clinical trial services, in an effort to provide a comprehensive outsourcing solution for topical Phase I study needs in a GCP and GLP compliant environment.

“Our significant experience in conducting clinical trials, combined with Synomics Pharma’s robust quality system, responsive team, and state-of-the-art bioanalysis techniques, creates an exceptional resource for outsourcing Phase I clinical trials,” said Daryl Paulson, Ph.D., chief executive officer of BioScience Laboratories.

“Synomics Pharma’s comprehensive quality management system reduces regulatory risk,” said John Pirro, vice president and chief operating officer of Synomics Pharma. “Our active involvement with the Bioanalytical Quality Standards Initiative for the implementation of ICH Q10 for clinical trials demonstrates our commitment to consistency and quality in clinical bioanalysis. The alliance between Synomics Pharma and BioScience Laboratories produces a versatile topical clinical Phase I study service offering that will be highly beneficial to the industry.”